NCT05724797View on ClinicalTrials.gov

Single Ascending Dose Study of NRS 033 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

NRS-033

A single dose of NRS-033 will be administered

DRUG

Placebo

A single dose of matching placebo will be administered

Trial Locations (1)

07094

Frontage Clinical Research Center, Secaucus

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Nirsum Labs

INDUSTRY